Volume 28, Number 9—September 2022
Research
Rapid Adaptation of Established High-Throughput Molecular Testing Infrastructure for Monkeypox Virus Detection
Table 3
Hit rates during limit of detection studies of dual-target MPXV assay rapidly adapted from established high-throughput molecular testing infrastructure*
Concentration, copies/mL | NVAR | MPXV | Overall |
---|---|---|---|
100 | 21/21 | 21/21 | 21/21 |
50 | 21/21 | 21/21 | 21/21 |
25 | 21/21 | 21/21 | 21/21 |
12.5 | 20/21 | 21/21 | 21/21 |
6.25 | 19/21 | 20/21 | 21/21 |
3.125 | 11/21 | 13/21 | 15/21 |
1.56 | 11/21 | 11/21 | 17/21 |
0.78 | 3/21 | 6/21 | 7/21 |
*Results represent no. positive/no. tested. Limits of detection were determined by serial dilution of a quantified MPXV standard (quantified by digital PCR) as a reference. Concentrations represent copies/mL of specimen. Dilution series were generated automatically using a STARlet Liquid Handler (Hamilton, https://www.hamiltoncompany.com). We calculated 95% probability of detection by using MedCalc statistical software (https://www.medcalc.org). MPXV, monkeypox virus; NVAR, nonvariola orthopoxvirus.